KALIOS.HEALTH

Written by G · Checked

No vendors · No affiliates · No vendor pays for a word of it

Method

How we check

The checks behind the pages on Kalios: what runs on every build, the rules the writing follows, what a new page goes through, and what the marks on a page mean.

The readPaper follows your phone · Aa flips it

The citation gate

Every PubMed ID, PubMed Central ID and DOI on every page is looked up in the record of the service that issued it: PubMed and PubMed Central for their IDs, the DOI registries for DOIs. A record is fetched once and kept. On every run, each citation is then held against its record: the paper’s title, first author and year must match the reference or the sentence citing it, and an author named beside an ID must be one of the paper’s.

An ID that opens no paper, or a different paper, fails the run, and nothing ships while it fails. A citation the check can’t confirm passes only after a check by hand, with its reason written down; most are the right paper, cited in a sentence that doesn’t carry the title or the first author the check compares.

Its last full run, on 12 Oct 2026: 5,825 citations checked on 180 pages, 0 failing; 111 passed on a reason written down after a check by hand.

Doses

The rule for a dose on a Kalios page has three parts.

  • Cited. A figure from a trial or a label is cited where it appears, with the people it was given to: how many, and who. An animal dose names its species.
  • Attributed. A figure from anywhere else, such as a seller’s listing, a clinic’s published schedule or user reports compiled online, is named as theirs, in words that describe rather than instruct.
  • Cut. A figure with neither behind it is not on the page.

When the rule went through the dosing, protocol and monitoring text of 89 pages in October 2026, it made 3,429 edits: 1,248 added a citation, 794 an attribution, 709 reworded a line and 678 cut one. The 21 compound pages added after it were written under it.

New pages: two verifiers

A new compound page is written from its sources, then read by two verifiers, each on its own. One holds every claim against the source it cites: the paper, the label, the trial record. The other holds the page against the site’s rules and the law: every dose with its population, no instruction in Kalios’s voice, no vendor named, the legal status checked again against the FDA’s own records. A fixer corrects what they find, and a fresh verifier reads the page again.

The 21 compound pages added in October 2026 went through it. In the last round alone the verifiers raised 482 findings, 11 to 52 a page. Four of those pages went live before their last read finished; it found errors on all four, and the fixes are on the corrections page.

Corrections

Every correction to a page goes on the corrections page: the date, the page, what it said and what it says now. A claim changed because it was wrong gets an entry. The strip at the top of each compound, stack and pair page counts that page’s entries and links them; a page with none says so.

995 corrections logged so far, on 161 pages.

A reader who finds an error can send the source to kaliospeptides@proton.me.

What “Checked” means

The date in the strip at the top of a page is the day its own text last changed: a corrected figure, a new study, a claim cut. The parts drawn from the site’s shared data don’t move it: the header and footer, the lines under the stamps, the cards, the author box. Neither does a structural change that leaves what the page says as it was. On the pages that list others, such as the homepage, the compound list and the goal pages, any change to what they list moves it. A compound page’s closing line carries the same date.

The three stamps

Every compound carries one of three legal stamps, for where it stands in the US today, each with its line:

  • FDA approved: Prescribed by a doctor, made by a manufacturer. On a card, “for another use” under it means the approval is for a different use from the one on the card’s tag.
  • Compounded Rx: On FDA’s 503A list — a licensed pharmacy can compound it for you.
  • Gray market: one of three lines.
    • FDA panel said yes on July 23–24, 2026 — not legal yet
    • FDA said no — on the do-not-compound list
    • No FDA ruling — not on any list
    Under it on a compound or stack page: “Sold as a research chemical. Some clinics and pharmacies still supply it; that’s their risk, not a change in the rule.”

A stack carries the stamp and line of its most restrictive member, named. Where a compound’s own facts don’t fit its stamp’s line, the line under its name says what does.

The receipt

The stack receipt puts one question first: has a study given these two to people together? It counts only such a study, among the sources Kalios cites. When there is none, it says “none published”, with this line:

“None published: no study that gave them to people together is among the sources Kalios cites. Reports of people already taking both, registered trials, conference talks, patents and makers’ own tests don’t count.”

How the work is done

The reading is done by machines, at a scale no editorial team could match: the sources fetched and read, every citation ID held against its paper, every verifier’s pass. The judgment is a person’s: what gets a page, what gets a flag, what the site refuses to say. When it’s wrong, it is on the corrections page.